# SS-31 TAZPOWER extension: Barth syndrome at 168 weeks

Source: https://pepvault.app/research/ss-31-tazpower-2024

Last updated: 2026-11-18

Use: © PepVault. Read and cite with a link. Copying, bulk scraping, rewriting or republishing is not permitted (https://pepvault.app/terms#content).

[Research](https://pepvault.app/research) [SS-31](https://pepvault.app/research#ss-31)

Clinical trial · people

# SS-31: 96.1 m longer 6-minute walk at 168 weeks in TAZPOWER

Checked against the paper November 2026 Clinical trial [Published by PepVault](https://pepvault.app/guides/how-we-research)

## The takeaway

For Barth syndrome, this small extension suggests elamipretide's gains in walking distance and fatigue held up through 168 weeks, with injection-site reactions as the most common side effect.

- **Kind:** Clinical trial
- **Studied in:** People
- **Published:** 2024
- **Journal:** Genet Med

## What they tested

The team wanted to know whether elamipretide (SS-31) stays safe and keeps working over the long term in people with Barth syndrome.

## How the study was done

An open-label extension, where everyone knew they were on the drug, followed a 28-week randomized, placebo-controlled trial called TAZPOWER. Patients who entered the extension kept taking the trial's 40 mg dose of elamipretide under the skin each day for up to 168 weeks, and 8 of them reached the week 168 visit.

<!--promo-->

PepVault for iPhone

## Taking SS-31? Keep your own record

Log each dose, your weight and how you feel, in one place.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=study-card-flow&mt=8)

7 days free on the yearly plan for new subscribers.

<!--/promo-->

## What they found

Elamipretide was well tolerated, and reactions at the injection site were the most common side effect. The 6-minute walk test, which measures how far a person walks in 6 minutes, improved significantly at every visit compared with the start of the extension, reaching a total gain of 96.1 m at week 168. Average scores on a Barth syndrome fatigue questionnaire stayed better than at the start at every visit. Heart volumes measured by 3D echocardiography, an ultrasound of the heart, trended significantly toward improvement by week 168, and the MLCL/CL biomarker ratio also improved and tracked with key clinical outcomes.

## What it doesn’t show

This was a very small group, with only 8 people reaching the final visit, and the extension had no placebo arm, so the gains can't be cleanly separated from other causes. Patients and doctors knew the treatment, which can shape how symptoms like fatigue are rated.

## The paper

Thompson et al. Long-term efficacy and safety of elamipretide in patients with Barth syndrome: 168-week open-label extension results of TAZPOWER. Genet Med. 2024.

- [PubMed (PMID 38602181)](https://pubmed.ncbi.nlm.nih.gov/38602181/)
- [The paper (DOI 10.1016/j.gim.2024.101138)](https://doi.org/10.1016/j.gim.2024.101138)
- [ClinicalTrials.gov (NCT03098797)](https://clinicaltrials.gov/study/NCT03098797)

## The compound

- [SS-31: how it works, half-life, studied range and evidence](https://pepvault.app/peptides/ss-31)
- [SS-31 dose guide](https://pepvault.app/lab/dosage/ss-31)

## With this study

### SS-31

- [SS-31: the full reference](https://pepvault.app/peptides/ss-31)
- [SS-31 dose guide](https://pepvault.app/lab/dosage/ss-31)

### Mixing charts

- [10 mg vial](https://pepvault.app/tools/reconstitution-calculator/ss-31-10mg)
- [50 mg vial](https://pepvault.app/tools/reconstitution-calculator/ss-31-50mg)

### Studies

- [SS-31 (elamipretide) eye drops missed main vision goal in LHON trial](https://pepvault.app/research/ss-31-karanjia-2024)
- [SS-31: no gain in walk distance or fatigue in the MMPOWER-3 trial](https://pepvault.app/research/ss-31-mmpower-3-2023)
- [SS-31: wearable data grouped responders with 100% accuracy](https://pepvault.app/research/ss-31-van-den-eynde-2023)
- [All 14 studies](https://pepvault.app/research#ss-31)

### Compared with

- [MOTS-c vs SS-31](https://pepvault.app/peptides/compare/mots-c-vs-ss-31)

### Tools

- [Reconstitution calculator](https://pepvault.app/tools/reconstitution-calculator)
- [How long will my vial last?](https://pepvault.app/tools/how-long-will-my-vial-last)
- [Is my mixed vial still good?](https://pepvault.app/tools/reconstituted-peptide-expiry)
- [Half-life calculator](https://pepvault.app/tools/peptide-half-life-calculator)

### Terms on this page

- [Placebo](https://pepvault.app/glossary/placebo)
- [Open-label](https://pepvault.app/glossary/open-label)

## More studies on SS-31

- [SS-31 (elamipretide) eye drops missed main vision goal in LHON trial](https://pepvault.app/research/ss-31-karanjia-2024) Randomized trial · people · 2024
- [SS-31: no gain in walk distance or fatigue in the MMPOWER-3 trial](https://pepvault.app/research/ss-31-mmpower-3-2023) Randomized trial · people · 2023
- [SS-31: wearable data grouped responders with 100% accuracy](https://pepvault.app/research/ss-31-van-den-eynde-2023) Randomized trial · people · 2023
- [SS-31: no 12-week benefit, walk gains by 36 weeks open-label](https://pepvault.app/research/ss-31-reid-thompson-2021) Randomized trial · people · 2021
- [SS-31 raised muscle ATP capacity after one dose in older adults](https://pepvault.app/research/ss-31-roshanravan-2021) Randomized trial · people · 2021
- [SS-31: walk distance rose with dose in 5-day MMPOWER trial](https://pepvault.app/research/ss-31-mmpower-2018) Randomized trial · people · 2018
- [Every study on SS-31](https://pepvault.app/research#ss-31)

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed November 2026. Spot an error? [feedback@pepvault.app](mailto:feedback@pepvault.app). [How we research](https://pepvault.app/guides/how-we-research). This page reports one study; it is not medical advice.

<!--promo-->

[Track it in the app](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=study-card-next&mt=8)

<!--/promo-->

<!--promo-->

PepVault for iPhone

## Taking SS-31? Keep your own record

Log each dose, your weight and how you feel, in one place.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=study-card-end&mt=8)

7 days free on the yearly plan for new subscribers.

[Explore the live demo](https://pepvault.app/login)

<!--/promo-->

<!--promo-->

PepVault for iPhone

## Taking SS-31? Keep your own record

Log each dose, your weight and how you feel, in one place.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=study-card-rail&mt=8)

7 days free on the yearly plan for new subscribers.

<!--/promo-->

## With this study

### SS-31

- [SS-31: the full reference](https://pepvault.app/peptides/ss-31)
- [SS-31 dose guide](https://pepvault.app/lab/dosage/ss-31)

### Mixing charts

- [10 mg vial](https://pepvault.app/tools/reconstitution-calculator/ss-31-10mg)
- [50 mg vial](https://pepvault.app/tools/reconstitution-calculator/ss-31-50mg)

### Studies

- [SS-31 (elamipretide) eye drops missed main vision goal in LHON trial](https://pepvault.app/research/ss-31-karanjia-2024)
- [SS-31: no gain in walk distance or fatigue in the MMPOWER-3 trial](https://pepvault.app/research/ss-31-mmpower-3-2023)
- [SS-31: wearable data grouped responders with 100% accuracy](https://pepvault.app/research/ss-31-van-den-eynde-2023)
- [All 14 studies](https://pepvault.app/research#ss-31)

### Compared with

- [MOTS-c vs SS-31](https://pepvault.app/peptides/compare/mots-c-vs-ss-31)

### Tools

- [Reconstitution calculator](https://pepvault.app/tools/reconstitution-calculator)
- [How long will my vial last?](https://pepvault.app/tools/how-long-will-my-vial-last)
- [Is my mixed vial still good?](https://pepvault.app/tools/reconstituted-peptide-expiry)
- [Half-life calculator](https://pepvault.app/tools/peptide-half-life-calculator)

### Terms on this page

- [Placebo](https://pepvault.app/glossary/placebo)
- [Open-label](https://pepvault.app/glossary/open-label)

<!--promo-->

PepVault for iPhone

## Taking SS-31? Keep your own record

Log each dose, your weight and how you feel, in one place.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=study-card-sticky&mt=8)

7 days free on the yearly plan for new subscribers.

[Explore the live demo](https://pepvault.app/login)

<!--/promo-->

## Research

- [All studies](https://pepvault.app/research)
- [Every study on SS-31](https://pepvault.app/research#ss-31)

## The library

- [SS-31](https://pepvault.app/peptides/ss-31)
- [SS-31 dose guide](https://pepvault.app/lab/dosage/ss-31)
- [The peptide reference library](https://pepvault.app/peptides)

## How we work

- [How we research](https://pepvault.app/guides/how-we-research)
- [How we check the library](https://pepvault.app/about#library)

PepVault is a research and tracking resource, not medical advice. Ranges are what studies used, never a dose for you. Brand names are trademarks of their owners; PepVault is independent of them.

PepVault is a private research and tracking tool, not medical advice. The information here is reference material from published literature and community use — always verify it and discuss any protocol with a qualified clinician before changing it.

© 2026 PepVault. Our text, data and tools may not be copied, scraped or republished without [permission](https://pepvault.app/terms#content).
